Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 3/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | RECQL | P46063 | 2/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.86 |
| ▸ | CASP1 | P29466 | 1/20 | 0.86 |
| ▸ | HTT | P42858 | 1/20 | 0.86 |
| ▸ | BLM | P54132 | 1/20 | 0.86 |
| ▸ | CASP7 | P55210 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.86 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.86 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502640 | 1.00 | GRB2 (0.86) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| SCHEMBL29352907 | 1.00 | GRB2 (0.86) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| SCHEMBL29352655 | 1.00 | GRB2 (0.86) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6939686 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3845 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL13659669 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL19770615 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6152 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3844 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL27304406 | 0.93 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3256850-B1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12352679-B2 | Synthetic human cell mimic particle for cytometric or coulter device | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250189428-A1 | COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250164373-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-3864140-B1 | ANALYSIS OF VIABLE AND NONVIABLE CELLS | SAGEMEDIC CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250093251-A1 | SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME IMMUNE CELL ACTIVATION | SLINGSHOT BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12196661-B2 | Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240353305-A1 | SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME FOR IMMUNE CELL ACTIVATION | SLINGSHOT BIOSCIENCES, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12066369-B2 | Synthetic human cell mimic particle for cytometric or coulter device | SLINGSHOT BIOSCIENCES, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20180275040-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3256850-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | Slingshot Biosciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9714897-B2 | Hydrogel particles with tunable optical properties and methods for using the same | SLINGSHOT BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170143735-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS (ES) | 2017-05-25 | — | — | US | disclosed |
| EP-3160472-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | Institut De Recerca Contra La Leucemia Josep Carreras (ES) | 2017-05-03 | — | — | EP | disclosed |
| CN-106471373-A | For treat, diagnose and prognosis Malignancy method | 约瑟卡雷拉斯白血球过多症研究所 | 2017-03-01 | — | — | CN | disclosed |
| US-20160258856-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| WO-2016130489-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-2959904-A1 | Methods for treating, diagnosing and prognosing a haematological malignancy | Institut De Recerca Contra La Leucemia Josep Carreras (ES) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015197839-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | CD4, ICOS, CD69 | GRB2 1405/4885MAPT 1949/4885RECQL 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.